NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. NanoViricides emphasized NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
According to the company, NV-387 is a broad-spectrum antiviral drug being developed for the treatment of RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox infections and measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. The announcement comes amid an outbreak of the Bundibugyo ebolavirus species, which has a higher mortality rate than the more common Zaire ebolavirus.
NanoViricides’ technology is based on proprietary nanomaterials designed to mimic host cell receptors, thereby binding and neutralizing viruses. The company’s lead drug candidate, NV-387, is a nanoviricide that does not encapsulate remdesivir, while NV-CoV-2-R is a separate candidate that encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, NV-CoV-2-R is likely to be an approvable drug if safety is comparable.
NanoViricides holds a worldwide exclusive perpetual license to TheraCour nanomedicine technology for several drugs targeting specific viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, influenza, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses. The company intends to obtain licenses for RSV, poxviruses, and enteroviruses if initial research is successful.
The company noted that the path to typical drug development is extremely lengthy and requires substantial capital. As with any drug development efforts, there can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance that successful results against coronavirus in the lab will lead to successful clinical trials or a successful pharmaceutical product.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/mm3Z5.
